[1] Spain DM. The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs[J]. Am Rev Tuberc, 1957, 76(4): 559-566.

[2] MacKenzie B, Korfei M, Henneke I,et al. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis[J]. Respir Res,2015(16):83.

[3] Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis[J].Annu Rev Pathol, 2014(9): 157-179.

[4] O'Connor JW, Gomez EW.Biomechanics of TGFβ-induced epithelialmesenchymal transition: implications for fibrosis and cancer[J].Clin Transl Med, 2014(3):23.

[5] Kawasaki H, Ogura T, Yokose T, et al. P53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis[J]. Hum Pathol, 2001, 32 (10):1043-1049.

[6] Pandit KV, Milosevic J. MicroRNA regulatory networks in idiopathic pulmonary fibrosis[J]. Biochem Cell Biol, 2015,93(2):129-137.

[7] Camelo A, Dunmore R, Sleeman MA, et al. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier[J]. Front Pharmacol, 2014, 10(4):173.

[8] Armanios M. Telomerase and idiopathic pulmonary fibrosis[J].Mutat Res,2012,730 (1/2): 52-58.

[9] Nishio Y, Nakanishi K, Ozeki Y, et al. Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors[J]. Jpn J Clin Oncol, 2007,37(1): 16-22.

[10] Lebeche D, Malpel S, Cardoso WV. Fibroblast growth factor interactions in the developing lung[J]. Mech Dev,1999,86(1/2):125-136.

[11] Ju W, Zhihong Y, Zhiyou Z,et al. Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis[J]. Mol Med,2012(18):992-1002.

[12] Antoniou KM, Margaritopoulos GA, Soufla G, et al. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF) [J]. Recept Signal Transduct Res,2010,30(4):262-269.

[13] Wollin L, Maillet I, Quesniaux V, et al. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor, nintedanib, in experimental models of lung fibrosis[J]. Pharmacol Exp Ther,2014,349(2):209-220.

[14] Lasky JA, Tonthat B, Liu JY, et al. Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats[J]. Am J Respir Crit Care Med,1998,157(5 Pt 1):1652-1657.

[15] Antoniou KM, Soufla G, Proklou A,et al. Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study[J]. Clin Dev Immunol,2009:537929. doi: 10.1155/2009/537929.

[16] Hostettler KE, Zhong J, Papakonstantinou E, et al.Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis[J]. Respir Res,2014(15):157.

[17] 崔本科, 赵洪文.肺癌合井肺间质纤维化引例临床分析[A].中华医学会呼吸病学年会(第十四次全国呼吸病学学术会议)论文汇编[C].辽宁:大连, 2013:260.

[18] Lee T, Park JY, Lee HY,etal. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival[J]. Respir Med,2014,108(10):1549-1555.

[19] Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis[J]. Eur Respir J, 2001,17(6):1216-1219.

[20] Oh SY, Kim MY, Kim JE,etal. Evolving early lung cancers detected during follow-up of idiopathic interstitial pneumonia: serial CT features[J]. AJR Am J Roentgenol,2015,204(6):1190-1196.

[21] Watanabe A, Higami T, Ohori S,et al.Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? [J].J Thorac Cardiovasc Surg, 2008,136(5):1357-1363.

[22] Yamada Y, Terada J, Tatsumi K, et al. Respiratory bronchiolitis and lung carcinoma[J].Respir Investig,2013,51(3):184-190.

[23] Kinoshita Y, Kishi K, Takaya H,et al.A case of desquamative interstitial pneumonia with adenocarcinoma of the lung[J].Nihon Kokyuki Gakkai Zasshi, 2007,45(11):861-865.

[24] Tsuda T, Mino Y, Babazono A, et al. A case-control study of lung cancer in relation to silica exposure and silicosis in a rural area in Japan[J].Ann Epidemiol, 2002,12(5):288-294.

[25] Maeda M, Nishimura Y, Kumagai N, et al. Dysregulation of the immune system caused by silica and asbestos[J].J Immunotoxicol,2010, 7(4):268-278.

[26] Gambelunghe A, Antognelli C, Del Buono C, et al. Crystalline silica can induce oxidative stress by inhibiting glyoxalase system in bronchial epithelial cells[J]. G Ital Med Lan Ergon,2007,29(3 Suppl):397-399.

[27] Fanizza C, Ursini CL, Paba E, et al. Cytotoxicity and DNA-damage in human lung epithelial cells exposed to respirable α-quartz[J]. Toxicol In Vitro, 2007,21(4):586-594.

[28] Case BW, Abraham JL, Meeker G,et al. Applying definitions of'asbestos'to environmental and'low-dose'exposure levels and health effects,particularly malignant mesothelioma[J]. Toxicol Environ Health, 2011,14(1-4):3-39.

[29] Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria[J]. Oncology(Willson Park), 2011, 25(5):400-413.

[30] Huang SX, Jaurand MC, Kamp DW, et al. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases[J].J Toxicol Environ Health B Crit Rev, 2011, 14(1-4):179-245.

[31] Brincker H. Coexistence of sarcoidosis and malignant disease: causality or coincidence? [J].Sarcoidosis, 1989,6(1):31-43.

[32] Brincker H, Wilbek E. The incidence of malignant tumours in patients with sarcoidosis[J].Ugeskr Laeg,1974,136(39):2192-2195.

[33] Boffetta P, Rabkin CS, Gridley G. A cohort study of cancer among sarcoidosis patients[J]. Int J Cancer, 2009,124(11):2697 -2700.

[34] Yang Y, Fujita J, Tokuda M, et al. Lung cancer associated with several connective tissue disease:with a review of literature[J]. Rheumatol Int,2001,21(3):106-111.

[35] Huang YL, Chen YJ, Lin MW,et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan:a nationwide population-based study[J]. Br J Dermatol,2009,161(4): 854-860.

[36] Antiochos BB, Brown LA, Li Z, etal.Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA[J]. J Rheumatol, 2009,36(12):2704-2710.

[37] Fujita J, Tokuda M, Bandoh S,et al. Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature[J]. Rheumatol Int, 2001, 20(2):81-84.

[38] Yamada T, Nakajima A, Inoue E, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis[J]. Rheumatol Int, 2011,31:1487-1492.

[39] Romer FK, Hommelgaard P, Schou G.Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients[J]. Eur Respir J,1998,12(4):906-912.

[40] Bernatsky S,Ramsey-Goldman R,Clarke AE.Malignancy in systemic lupus erythematosus: what have we learned? [J]. Best Practi Res Clin Rheumatol,2009,23(4):539-547.

[41] Ragnarsson O, Gröndal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus[J]. Lupus, 2003,12(9):687-691.